Q1 2026 earnings call recap: raised revenue growth guidance, Omnipod 5 Libre 3 Plus integration, margins, risks & Q2 headwind—read now.

Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Read more on ...

TheFly reported on May 7 that PODD saw its valuation outlook revised as Goldman Sachs reduced its price target to $237 from ...

We recently compiled a list of the 8 Most Oversold Large Cap Stocks to Buy. Insulet Corporation (NASDAQ:PODD) is one of the ...

Insulet (NASDAQ:PODD) reported what executives described as a “strong start” to fiscal 2026, posting double-digit revenue ...

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has enrolled the first participant in a pivotal study for its ...

Insulet’s first quarter was marked by robust revenue growth, driven by continued adoption of its Omnipod 5 insulin delivery ...

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide ...

Insulet’s latest earnings call carried an upbeat tone, with management emphasizing powerful revenue growth, expanding margins, and a fast-advancing product pipeline. While executives acknowledged ...

Insulet enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 ...

Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on ...